Reuters logo
BRIEF-Paion reports positive headline data in US clinical safety trial of Remimazolam
March 27, 2017 / 5:39 AM / 9 months ago

BRIEF-Paion reports positive headline data in US clinical safety trial of Remimazolam

March 27 (Reuters) - Paion AG:

* Reports positive headline data in U.S. clinical safety trial of Remimazolam in high-risk patients undergoing colonoscopy

* Remimazolam administration appeared safe

* Efficacy and efficiency gains comparable to confirmatory U.S. phase III pivotal trial

* Overall, Remimazolam demonstrated good respiratory and cardiovascular stability as compared to placebo with Midazolam rescue

* No adverse events of concern were observed in either group Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below